When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

最后审阅: 9 Apr 2025
最后更新: 08 Feb 2022

小结

定义

病史和体格检查

关键诊断因素

  • presence of risk factors
  • acral and periorificial depigmentation
  • perianal and genital depigmentation
  • recent cutaneous trauma
  • localised sunburn pain
  • enhancement and fluorescence with UV-A exposure
  • halo naevus
  • universal depigmentation
完整详情

危险因素

  • age <30 years
  • family history of vitiligo
  • autoimmune disease
  • chemical contact
完整详情

诊断性检查

首要检查

  • clinical diagnosis
完整详情

需考虑的检查

  • Wood’s lamp examination
  • skin biopsy
完整详情

治疗流程

持续性治疗

segmental vitiligo or limited vitiligo

widespread vitiligo (more than 3% body surface area)

撰稿人

作者

John E. Harris, MD, PhD

Professor

Department of Dermatology

University of Massachusetts Medical School

Worcester

MA

利益声明

JEH has acted as a consultant and/or investigator for: Pfizer, Genzyme/Sanofi, Aclaris Therapeutics Inc., Incyte, Rheos Medicines, Sun Pharmaceuticals, LEO Pharma, Villaris Therapeutics Inc., Dermavant, Temprian, AbbVie Inc., Janssen, TeVido, BioDevices, EMD Serono, Almirall, Boston Pharma, Sonoma Biotherapeutics Inc., Methuselah Health, Twi Biotech, Pandion, Cogen Therapeutics Inc., Admirx, BridgeBio, AnaptysBio, Avita, Frazier Management. He has equity in TeVido Biodevices, Rheos, and Villaris Therapeutics Inc., and is the Scientific Founder of Villaris Therapeutics Inc. JEH is an author of a number of references cited in this topic.

Mehdi Rashighi, MD

Assistant Professor

Department of Dermatology

University of Massachusetts Medical School

Worcester

MA

利益声明

MR has received consulting fees and/or research grants from the following: Pfizer, AbbVie, Dermavant, LEO Pharma, and Almirall. MR is an author of a reference cited in this topic.

鸣谢

Professor John E. Harris and Dr Mehdi Rashighi would like to gratefully acknowledge Dr Bernhard Ortel, a previous contributor to this topic. BO declares that he has no competing interests.

同行评议者

Iltefat Hamzavi, MD

Senior Staff Physician

Multicultural Dermatology Center

Henry Ford Hospital

Detroit

MI

利益声明

IH is an author of a number of references cited in this topic.

Piergiacomo Calzavara-Pinton, MD

Chair

Dermatology Department

University of Brescia

Brescia

Italy

利益声明

PC-P is an author of a number of references cited in this topic.

参考文献

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

关键文献

Ortonne J-P. Vitiligo and other disorders of hypopigmentation. In: Bolognia JL, Jorrizzo JL, Rapini RP, eds. Dermatology. New York, NY: Mosby; 2008:913-38.

Taieb A, Picardo M. Clinical practice: vitiligo. N Engl J Med. 2009 Jan 8;360(2):160-9. 摘要

Taieb A, Alomar A, Böhm M, et al; Vitiligo European Task Force (VETF); European Academy of Dermatology and Venereology (EADV); Union Européenne des Médecins Spécialistes (UEMS). Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol. 2013 Jan;168(1):5-19.全文  摘要

Whitton ME, Pinart M, Batchelor J, et al. Interventions for vitiligo. Cochrane Database Syst Rev. 2015 Feb 24;(2):CD003263.全文  摘要

参考文献

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.

内容使用需遵循免责声明